Indivior Pharmaceuticals, based in Richmond, Va., announced it will pay a special cash dividend of $8.13 per share of common stock, contingent on the completion of its merger with Supernus Pharmaceuticals, Inc.
In a joint proxy statement and prospectus filed with the Securities and Exchange Commission on Sept. 11, 2026, Indivior set Oct. 30 as the record date for the dividend. The payment is expected around Nov. 6, 2026, provided the merger closes on or about Nov. 2, subject to stockholder approvals and other customary conditions.
Indivior stressed that the dividend will not be paid if the merger fails to close for any reason. Equity award holders with outstanding Indivior awards as of the record date will also receive $8.13 per share underlying those awards, payable when the awards vest. Shares of Indivior common stock issued as merger consideration to Supernus stockholders will not be entitled to the special dividend.
The transaction requires approval from both sides: Indivior stockholders must authorize the issuance of its common stock, and Supernus stockholders must adopt the merger agreement.
Indivior develops and markets treatments for opioid use disorder.
